Search Browse Earnings

AYTU BIOPHARMA, INC — SlamSEC

AYTU BIOPHARMA, INC

Nasdaq:AYTU

Pharmaceutical Preparations·DENVER, CO

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$65.2M

-39.3% YoY

FY 2025

Adj. EBITDA

$7.2M

11.1% margin

FY 2025

Net Income

-$15.8M

-24.3% margin

FY 2025

EPS (Diluted)

-$74.01

FY 2023

Stock Price

$2.60

-1.3%

2026-03-10

52W Range

$0.95 – $3.06

P/E Ratio

-0.0x

Market Cap

$28.0M

Cash

$20.0M

FY 2025

Total Debt

$10.9M

FY 2025

Net Cash

$9.1M

FY 2025

Enterprise Value

$18.8M

Debt / EBITDA

-1.3x

FY 2025

EV / EBITDA

2.6x

Employees

—

CEO

Disbrow Joshua R.

CFO

Selhorn Ryan J